P376 - Clinical evaluation of biosimilar anti-CD20 monoclonal antibody with Rituximab in the treatment of ANCA-Associated Vasculitis

Ms Rebecca Heath, Ms Anna Iacovou, Ms Caroline Ashley, Dr Marilina Antonelou, Professor Alan Salama
1Centre for Nephrology, Royal Free Hospital, University College London, London, United Kingdom, 2UK Renal Pharmacy UK Group, London, United Kingdom

Background:

Rituximab (RTX) an anti-CD20 monoclonal antibody has proven effective both for the induction and maintenance of remission in ANCA-associated vasculitis (AAV), refractory SLE and other glomerulonephritides. In April 2017, Truxima®, the first biosimilar version of rituximab launched in the UK. We performed a clinical evaluation of MabThera® compared to the newly licensed Truxima® in our centre.

Method

We conducted a retrospective review of 242 patients with AAV, SLE and other forms of glomerulonephritis. Each patient received at least one form of RTX (either MabThera© or Truxima©) between 2010 and 2018. The median (IQR) period of follow up was 2.9 (1.5-4.8) years. We collected data on patient demographics, cumulative doses, and clinical and biochemical outcomes after treatment. Outcomes were measured using CD19 depletion (defined as CD19+ cell count of <0.005x10⁹ cells/L in peripheral blood at 6 months), with a combination of eGFR, uPCR and immunoglobulin titres throughout treatment and at last follow-up (LTFU). We included rates of adverse events (including anaphylaxis, fever and rash) and relapses in each group. Relapses were defined as either clinical or biochemical evidence in the form of eGFR and/or uPCR. Rates of CD19 depletion, relapse and adverse events were compared between patients in the MabThera© and Truxima© groups.

Result

Of the 242 patients receiving anti-CD20 therapy, 192 (79.3%) patients received MabThera© and 45 (20.7%) Truxima© as the initial preparation of RTX treatment. There was a significant improvement in eGFR and reduction in proteinuria in both preparations at LTFU (both p<0.05). The percentage of patients who became CD19 B cell deplete at six months was 70.7% (116/164) in the MabThera© group and 94.3% (33/35) with Truxima© (p=0.002). There was one episode of reported anaphylaxis in the MabThera© group. There was no significant difference between the two preparations in AAV patients with regards to the proportion of B cell depleted patients at 6 months (Fischer’s exact test; p=0.5207). There was a reduction in proteinuria in MabThera© (p<0.001) and in Truxima© (p=0.05) in AAV patients at LTFU. A subpopulation comparison of the two preparations received by patients with AAV is shown in Table 1.

Conclusions

We report equivalence in clinical efficacy and safety of the biosimilar anti-CD20 monoclonal antibodies MabThera© and Truxima©, especially in the treatment of AAV. With biosimilars being used increasingly in clinical practice, this comparable profile can provide reassurance for the use of Truxima©, and improve cost-effective access to Rituximab.